erlotinib hydrochloride has been researched along with Cicatrix in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acquitter, M; Chiappa, AM; Dervout, C; Fleuret, C; Plantin, P | 1 |
| Anadkat, MJ; Hepper, DM; Wu, P | 1 |
2 other study(ies) available for erlotinib hydrochloride and Cicatrix
| Article | Year |
|---|---|
[Erlotinib-induced scarring alopecia with a folliculitis decalvans-like presentation].
Topics: Alopecia; Cicatrix; Erlotinib Hydrochloride; Erythema; Female; Folliculitis; Humans; Middle Aged; Neoplasm Recurrence, Local | 2020 |
Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Cicatrix; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2011 |